Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD70, a member of the TNF superfamily, is a costimulatory molecule that interacts with CD27 to regulate immune responses. It is transiently expressed on activated immune cells and overexpressed in various cancers, promoting tumor proliferation and survival. As such, CD70 is an attractive target for immunotherapy, including monoclonal antibodies and CAR-T cell therapies. However, T cell-derived CD70 may also act as an immune checkpoint molecule, potentially limiting inflammatory responses.
Monoclonal antibodies: Antibody-dependent cellular cytotoxicity (ADCC), Complement-dependent cytotoxicity (CDC); CAR-T cells: T-cell mediated cytotoxicity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD70 molecule (None).